Regenerative medicine Company Avita Medical Ltd. (ASX: AVH), (OTCQX:AVMXY) is pleased to report the presentation of results obtained with the use of ReCell® Spray-On Skin® at the recent Clinical Cosmetic & Reconstructive Expo held in London, England 11-12 October, 2013.
Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the initiation of a pilot field study for its product candidate NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) for the control of pain associated with osteoarthritis in cats.
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today the closing of a AUD$ 10,018,644 common stock placement to sophisticated and institutional investors through the issue of 107,727,358 shares at a price of AUD $0. 09 3 per share.
Read more about Avita Medical Announces AUD$ 10M Equity Financing
October 14, 2015: 9NEWS spoke exclusively to the first patient to undergo the new treatment that is giving hope to sufferers of back pain.
Harriet Alexander Sydney Morning Herald.
Published: October 14, 2015 6:34PM
Read more about Saluda spinal implant for pain relief heralded as ‘breakthrough’
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced it has received CE Mark authorization to market in Europe that will allow it to define and target its autologous cell suspension technology for particular clinical market segments.
Adherium Limited (ASX: ADR), a global leader in digital health technologies which address sub-optimal medication use in chronic disease; today announced that data from three independent studies demonstrating the efficacy of the Company’s Smartinhaler™ platform in paediatric asthma management will be presented at the European Respiratory Congress, taking place between 26-30 September in Amsterdam, The Netherlands.
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced approval from the U.S. Food and Drug Administration (FDA) for the expansion of its Compassionate Use Investigational Device Exemption (IDE) program for ReCell®.
Read more about Avita Medical CEO Adam Kelliher interviewed on CommSec